- Home
- PZZA vs SNDX Comparison
PZZA vs SNDX Comparison
Compare PZZA & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PZZA
- SNDX
- Stock Information
- Founded
- PZZA 1984
- SNDX 2005
- Country
- PZZA United States
- SNDX United States
- Employees
- PZZA N/A
- SNDX N/A
- Industry
- PZZA Restaurants
- SNDX Biotechnology: Pharmaceutical Preparations
- Sector
- PZZA Consumer Discretionary
- SNDX Health Care
- Exchange
- PZZA Nasdaq
- SNDX Nasdaq
- Market Cap
- PZZA 1.3B
- SNDX 1.2B
- IPO Year
- PZZA 1993
- SNDX 2016
- Fundamental
- Price
- PZZA $47.72
- SNDX $16.38
- Analyst Decision
- PZZA Buy
- SNDX Strong Buy
- Analyst Count
- PZZA 13
- SNDX 10
- Target Price
- PZZA $56.18
- SNDX $36.20
- AVG Volume (30 Days)
- PZZA 2.0M
- SNDX 2.6M
- Earning Date
- PZZA 02-27-2025
- SNDX 03-04-2025
- Dividend Yield
- PZZA 3.86%
- SNDX N/A
- EPS Growth
- PZZA 22.68
- SNDX N/A
- EPS
- PZZA 2.89
- SNDX N/A
- Revenue
- PZZA $2,099,938,999.00
- SNDX $16,000,000.00
- Revenue This Year
- PZZA N/A
- SNDX N/A
- Revenue Next Year
- PZZA $1.82
- SNDX N/A
- P/E Ratio
- PZZA $16.50
- SNDX N/A
- Revenue Growth
- PZZA 0.45
- SNDX N/A
- 52 Week Low
- PZZA $35.28
- SNDX $12.06
- 52 Week High
- PZZA $76.91
- SNDX $25.34
- Technical
- Relative Strength Index (RSI)
- PZZA 61.69
- SNDX 68.27
- Support Level
- PZZA $38.20
- SNDX $14.53
- Resistance Level
- PZZA $54.40
- SNDX $15.40
- Average True Range (ATR)
- PZZA 2.93
- SNDX 0.70
- MACD
- PZZA 1.01
- SNDX 0.13
- Stochastic Oscillator
- PZZA 59.73
- SNDX 82.93
About PZZA Papa John's International Inc.
Papa John's is one of the largest players in the global QSR, or quick-service restaurant, pizza market, boasting more than 5,900 restaurants across nearly 50 countries at the end of 2023. The firm operates a predominantly franchised system, owning 11% of its restaurants and generating revenue from franchise royalties, sales of pizza and related products at its company-owned stores, and sales from its commissary supply chain. The firm is the fourth-largest limited-service pizza chain both in the US and globally, with a sizable presence in the UK, China, South Korea, and Chile.
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The company's product candidates are entinostat which has direct effects on both cancer cells and immune regulatory cells, SNDX-6352 and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Business activity of the group is primarily functioned through the region of United States.